Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monogram edges closer to HIV market:

This article was originally published in Clinica

Executive Summary

Monogram Biosciences has taken yet another step closer to marketing its HIV test for predicting response to a new type of drug being developed by Pfizer, after the pharmaceutical was issued an approvable letter by the US FDA. Its co-receptor tropism assay, Trofile, was used to select the more than 2,000 clinical trial patients worldwide who have received treatment with the drug - a CCR5-antagonist called maraviroc. Trofile will be made commercially available after the drug has received a definitive approval, which is pending the resolution of outstanding questions and the finalisation of product labelling between Pfizer and the FDA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel